Yongin, South Korea – September 11, 2026 -- GCCL (Global Clinical Central Lab), a South Korea-based clinical trial sample analysis provider, sponsored the Asia Bio Partnering Forum 2026 (ABP 2026) as a Platinum Sponsor, using the Singapore event to pursue expansion of its assay development and clinical sample analysis services across the Asia-Pacific region.
GCCL held partnering meetings with drug developers across mRNA, radiopharmaceutical and antibody therapy segments
The forum, held in Singapore from August 31 to September 2, drew approximately 650 pharmaceutical and biotechnology industry professionals, investors and life sciences stakeholders, generating roughly 2,500 one-on-one partnering meetings. GCCL engaged drug developers working across mRNA and nucleic acid therapeutics, radiopharmaceuticals and antibody-based therapies to assess evolving analytical requirements in global clinical development.
GCCL met global CROs and a Singapore government-affiliated economic development organization
The company held discussions with executives from global contract research organizations and Singapore-based pharmaceutical, diagnostics and clinical trial service firms to review existing partnerships and identify further collaboration. GCCL also engaged a Singapore government-affiliated economic development organization to explore support mechanisms for local biotech companies and deepen ties within the regional life sciences ecosystem.
GCCL sponsored the ABP 2026 Welcome Reception and showcased integrated lab capabilities
As Platinum Sponsor, GCCL backed the official ABP 2026 Welcome Reception, where Yuhwa Choi, Head of Business Operations at GCCL, delivered welcome remarks on the company's clinical sample analysis capabilities. At its exhibition booth, GCCL presented its integrated Central Lab, Bioanalytical Lab and R&D Lab operations, which support clinical trials from early- through late-stage development. The company held additional partnering discussions with pharmaceutical and biotechnology organizations from Korea, China, Japan, Singapore, Vietnam and Europe.
"ABP 2026 provided an important opportunity to engage directly with drug developers and global partners across the Asia-Pacific region and better understand their evolving analytical needs across increasingly diverse therapeutic modalities," said Yuhwa Choi, Head of Business Operations at GCCL.